Fisher Asset Management Portfolio holdings
Fisher Asset Management, LLC, operating as Fisher Investments, was founded in 1979 by Ken Fisher and is headquartered in Plano, Texas, following a relocation from Camas, Washington, in 2023. As an independent, fee-only investment adviser, it manages over $275 billion in assets for individual and institutional investors globally as of June 2024, offering tailored portfolio management through its Private Client Group and Institutional Group. Known for its active, top-down investment approach guided by a five-member Investment Policy Committee, the firm emphasizes asset allocation and has expanded internationally with offices in eight countries, including a wholly owned subsidiary, Fisher Investments Europe Limited, in London. With Ken Fisher as executive chairman and co-chief investment officer, succeeded as CEO by Damian Ornani in 2016, Fisher Investments blends a legacy of innovation with a client-first philosophy, recently spinning off its 401(k) Solutions into Fisher Retirement Solutions in 2024.
Top Buys
| 1 |
AbbVie
ABBV
|
+$1.88B |
| 2 |
Pfizer
PFE
|
+$1.41B |
| 3 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$1.17B |
| 4 |
Cisco
CSCO
|
+$1.1B |
| 5 |
Novartis
NVS
|
+$984M |
Top Sells
| 1 |
Abbott
ABT
|
+$1.21B |
| 2 |
Adobe
ADBE
|
+$1.06B |
| 3 |
Stryker
SYK
|
+$955M |
| 4 |
Boston Scientific
BSX
|
+$695M |
| 5 |
Banco Santander
SAN
|
+$684M |
Sector Composition
| 1 | Technology | 23.16% |
| 2 | Financials | 17.3% |
| 3 | Industrials | 10.45% |
| 4 | Healthcare | 9.91% |
| 5 | Energy | 8.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
ResMed
RMD
$28.8B
| $12.1M | ﹤0.01% |
54,106
-12,866
| -19% | -$3.21M |
|
377
iShares Core MSCI Europe ETF
IEUR
$8.62B
| $12.1M | ﹤0.01% |
172,138
-7,755
| -4% | -$566K |
|
378
Medtronic
MDT
$107B
| $12.1M | ﹤0.01% |
139,339
-85,662
| -38% | -$8.21M |
|
379
Associated Banc-Corp
ASB
$5.81B
| $12M | ﹤0.01% |
465,188
+107,068
| +30% | +$2.84M |
|
380
Insulet
PODD
$11.2B
| $12M | ﹤0.01% |
57,208
+4,473
| +8% | +$1.12M |
|
381
Outfront Media
OUT
$5.84B
| $11.9M | ﹤0.01% |
447,352
+13,519
| +3% | +$352K |
|
382
DexCom
DXCM
$29.5B
| $11.8M | ﹤0.01% |
188,645
-41,768
| -18% | -$2.91M |
|
383
Southern Company
SO
$109B
| $11.8M | ﹤0.01% |
122,639
+3,504
| +3% | +$324K |
|
|
CURB
384
Curbline Properties
CURB
$3.46B
| $11.7M | ﹤0.01% |
455,496
+8,602
| +2% | +$220K |
|
385
Renasant Corp
RNST
$3.92B
| $11.5M | ﹤0.01% |
318,000
-26,721
| -8% | -$1M |
|
386
Vanguard Long-Term Treasury ETF
VGLT
$10.2B
| $11.2M | ﹤0.01% |
202,959
-28,090
| -12% | -$1.58M |
|
387
Arcosa
ACA
$7.12B
| $11.1M | ﹤0.01% |
104,924
-2,529
| -2% | -$288K |
|
388
State Street SPDR S&P 500 ETF Trust
SPY
$781B
| $10.8M | ﹤0.01% |
16,646
-703
| -4% | -$478K |
|
389
Sunstone Hotel Investors
SHO
$2.11B
| $10.8M | ﹤0.01% |
1,197,071
-37,386
| -3% | -$343K |
|
390
The Greenbrier Companies
GBX
$1.49B
| $10.7M | ﹤0.01% |
203,511
-10,651
| -5% | -$563K |
|
391
Ionis Pharmaceuticals
IONS
$9.38B
| $10.6M | ﹤0.01% |
141,544
-71
| -0.1% | -$5.6K |
|
392
Incyte
INCY
$22.8B
| $10.6M | ﹤0.01% |
112,746
+31,572
| +39% | +$3.15M |
|
393
Edwards Lifesciences
EW
$52.9B
| $10.6M | ﹤0.01% |
132,199
-13,446
| -9% | -$1.11M |
|
394
Cousins Properties
CUZ
$5.02B
| $10.5M | ﹤0.01% |
465,898
-20,932
| -4% | -$508K |
|
395
Service Corp International
SCI
$11B
| $10.5M | ﹤0.01% |
127,093
-3,904
| -3% | -$315K |
|
396
Qualys
QLYS
$5.34B
| $10.2M | ﹤0.01% |
116,182
-2,561
| -2% | -$284K |
|
397
Steven Madden
SHOO
$3.1B
| $10.2M | ﹤0.01% |
300,000
-26,014
| -8% | -$1.01M |
|
398
Nuvalent
NUVL
$9.81B
| $9.99M | ﹤0.01% |
97,518
-3,188
| -3% | -$325K |
|
399
Yum! Brands
YUM
$44.6B
| $9.6M | ﹤0.01% |
61,714
+6,043
| +11% | +$957K |
|
400
Park Hotels & Resorts
PK
$2.86B
| $9.52M | ﹤0.01% |
904,247
-123,776
| -12% | -$1.37M |
|
Similar funds
